Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ: CSTL )

26.72 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Castle Biosciences, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences Inc.
Via Business Wire
Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Present at Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas
From Castle Biosciences Inc.
Via Business Wire
Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Reports Third Quarter 2023 Results
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2
From Castle Biosciences Inc.
Via Business Wire
New Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®
From Castle Biosciences Inc.
Via Business Wire
DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry
From Castle Biosciences Inc.
Via Business Wire
TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory
From Castle Biosciences Inc.
Via Business Wire
Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences’ IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression
From Castle Biosciences Inc.
Via Business Wire
TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus
From Castle Biosciences Inc
Via Business Wire
Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Reports Second Quarter 2023 Results
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Castle Biosciences Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Relmada, DoubleVerify, and Castle and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.